On 14 March 2024, Biocon Biologics announced that it has entered a long-term commercial collaboration with Eris Lifesciences, including to increase access to its biosimilars in India. The deal, worth INR 12,420 million, involves a 10-year supply agreement with Eris and over 430 Biocon employees transitioning to Eris.
In 2023, Biocon divested its Nephrology and Dermatology businesses to Eris (largely comprised of legacy small molecule brands). The March 2024 collaboration now extends the partnership to Biocon’s Metabolics, Oncology and Critical Care product portfolios in India.